Morgan Lam
ArriVent BioPharm
1
0
0
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (1)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Yongchang Zhang, MD
Hunan Cancer Hospital
Shared therapeutic areas:
Ciro Gallo, M.D., Ph.D.
University of Campania Luigi Vanvitelli
Shared therapeutic areas:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
Toshimitsu Tokimoto
Astrazeneca KK
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Zhaohui Zhu, MD
Peking Union Medical College Hospital
Shared therapeutic areas:
Zhengfei Zhu, MD
Fudan University
Shared therapeutic areas:
You Lu, MD
West China Hospital
Shared therapeutic areas:
Francesco Perrone, M.D., Ph.D
National Cancer Institute Naples, Italy; Director Clinical Trials Unit
Shared therapeutic areas:
Urielle Desalbres
Assistance Publique Hôpitaux de Marseille
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (1)
Showing 1 of 1 trials
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
All 1 trials loaded